Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Argan (AGX) Cash & Equivalents: 2010-2025

Historic Cash & Equivalents for Argan (AGX) over the last 16 years, with Jan 2025 value amounting to $145.3 million.

  • Argan's Cash & Equivalents rose 74.68% to $306.3 million in Q4 2025 from the same period last year, while for Oct 2025 it was $306.3 million, marking a year-over-year increase of 74.68%. This contributed to the annual value of $145.3 million for FY2025, which is 26.27% down from last year.
  • According to the latest figures from FY2025, Argan's Cash & Equivalents is $145.3 million, which was down 26.27% from $197.0 million recorded in FY2024.
  • In the past 5 years, Argan's Cash & Equivalents ranged from a high of $366.7 million in FY2021 and a low of $145.3 million during FY2025.
  • In the last 3 years, Argan's Cash & Equivalents had a median value of $173.9 million in 2023 and averaged $172.1 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first skyrocketed by 119.09% in 2021, then plummeted by 50.37% in 2023.
  • Argan's Cash & Equivalents (Yearly) stood at $366.7 million in 2021, then fell by 4.42% to $350.5 million in 2022, then slumped by 50.37% to $173.9 million in 2023, then grew by 13.27% to $197.0 million in 2024, then decreased by 26.27% to $145.3 million in 2025.